NASDAQ:ALIMAlimera Sciences Stock Price, Forecast & News

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALIM stock has increased by 9.9% and is now trading at $5.76. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alimera Sciences.

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Alimera Sciences.

Alimera Sciences Inc (NASDAQ:ALIM) announced its quarterly earnings data on Wednesday, April, 29th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.19. The biopharmaceutical company earned $14.54 million during the quarter, compared to the consensus estimate of $14.04 million. View Alimera Sciences' earnings history.

Shares of Alimera Sciences reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

Alimera Sciences updated its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14 million, compared to the consensus revenue estimate of $12.87 million.

2 equities research analysts have issued twelve-month price targets for Alimera Sciences' shares. Their forecasts range from $14.00 to $15.00. On average, they expect Alimera Sciences' share price to reach $14.50 in the next year. This suggests a possible upside of 151.7% from the stock's current price. View analysts' price targets for Alimera Sciences.

Media stories about ALIM stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alimera Sciences earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Alimera Sciences.

Alimera Sciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,300 shares, an increase of 37.5% from the June 15th total of 2,400 shares. Based on an average daily volume of 22,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short. View Alimera Sciences' Current Options Chain.

Some companies that are related to Alimera Sciences include TFF Pharmaceuticals (TFFP), Eton Pharmaceuticals (ETON), Savara (SVRA), Axovant Gene Therapies (AXGT), Aptorum Group (APM), Endonovo Therapeutics (ENDV), Checkpoint Therapeutics (CKPT), Recro Pharma (REPH), ContraFect (CFRX), SUMMIT THERAPEU/S (SMMT), Xeris Pharmaceuticals (XERS), Galmed Pharmaceuticals (GLMD), DiaMedica Therapeutics (DMAC), Onconova Therapeutics (ONTX) and Otonomy (OTIC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Amarin (AMRN), Agenus (AGEN), Opko Health (OPK), Advanced Micro Devices (AMD), Catalyst Pharmaceuticals (CPRX), CorMedix (CRMD) and Novavax (NVAX).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALIM stock can currently be purchased for approximately $5.76.

Alimera Sciences has a market capitalization of $28.97 million and generates $53.94 million in revenue each year. The biopharmaceutical company earns $-10,440,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Alimera Sciences employs 124 workers across the globe.

The official website for Alimera Sciences is www.alimerasciences.com.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]